Elicio Therapeutics, Inc.

ELTX

Explore Our Financial Data > Companies > Elicio Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ELTX
CIK	0001601485
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
Website	elicio.com
Phone	(857) 209-0050
CEO	Robert T. Connelly
Employees	23

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-51.28 million
Net Income	$-51.28 million
Net Income to Common	$-51.28 million
EPS	$-3.97

View All

Balance Sheet

Cash	$18.35 million
Assets	$28.14 million
Liabilities	$19.24 million
Common Equity	$8.90 million
Liabilities & Equity	$28.14 million

View All

Cash Flow Statement

Net Income	$-51.28 million
Cash From Operating Activities	$-35.06 million
Cash From Investing Activities	$-87,000.00
Cash From Financing Activities	$41.62 million
Change in Cash	$6.53 million

View All

Calculations

NOPAT	$-31.84 million
EBITDA	$-50.25 million
Price to Earnings	N/A
Price to Book	$16.17
ROE	-744.59%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS (“mKRAS”) driven pancreatic ductal adenocarcinoma (“PDAC”), one of th

Article Link

Elicio Therapeutics Secures $10 Million in Financing

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”

Article Link

Elicio Therapeutics: Q1 Earnings Snapshot

BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Tuesday reported a loss of $11.2 million in its first quarter. The Boston-based company said it had a loss of 87 cents per share.

Article Link

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnolo

Article Link

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher

Elicio Therapeutics (ELTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Article Link